Abstract

BackgroundTherapeutic advances have made low disease-activity states (LDAS) and remission increasingly common for patients with rheumatoid arthritis (RA) [1]. In order to achieve and maintain tight-control of disease activity, it...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call